CareLit · DOI-Nachweis · Klinische Neurophysiologie
Therapeutic Occupancy of the D2/3-preferring Dopamine Receptor Agonist Pramipexol Parkinson's Disease ([18F]-fallypride PET study)
DOI 10.1055/s-0032-1301629
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA Deutschländer, C La Fougere, G Xiong, K Bötzel, G Gründer, P Cumming
ZeitschriftKlinische Neurophysiologie
Ausgabe03/2012
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
It was the aim of the study to measure the occupancy of dopamine D2/3 receptors using the D2/3 receptor antagonist [18F]-fallypride (FP) and PET in patients with Parkinson's disease (PD) on and off medication with the D3-preferring agonist pramipexol. The therapeutic occupancy of brain dopamine receptors by various neuroleptics has been repeatedly investigated using [11C]-raclopride PET and [123I]-IBZM SPECT competi…
Zitieren
Zitierempfehlung
A Deutschländer, C La Fougere, G Xiong, K Bötzel, G Gründer, P Cumming (2012) Therapeutic Occupancy of the D2/3-preferring Dopamine Receptor Agonist Pramipexol Parkinson's Disease ([18F]-fallypride PET study). Klinische Neurophysiologie (03). https://doi.org/10.1055/s-0032-1301629
Mit CareLit weiterarbeiten